ClinicalTrials.gg
RecruitingNCT07949838CYC-ADEM-PedsUpdated Nov 19, 2026

Efficacy and Safety of Cyclophosphamide in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis (ADEM)

A Phase 2 interventional study of Cyclophosphamide and Intravenous immunoglobulin (IVIG) in Acute Disseminated Encephalomyelitis, sponsored by Damascus University. Recruiting at 1 site in Syria. Open to participants aged Up to 13 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Damascus University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Mar 2025, registered Nov 2026).
  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
Up to 13 Years
Sex
All
01

Study summary

Acute Disseminated Encephalomyelitis (ADEM) is a severe, immune-mediated demyelinating disease of the central nervous system predominantly affecting the pediatric population. Although high-dose intravenous corticosteroids (such as methylprednisolone) represent standard first-line therapy, a subset of clinical cases fails to achieve adequate clinical response, carrying high risks of persistent neurological disability, neurodevelopmental sequelae, or fulminant deterioration.

This randomized, open-label trial evaluates the clinical efficacy, neuroimaging outcomes, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a rescue modality in pediatric patients under 14 years of age with steroid-refractory ADEM. Eligible participants are allocated using a computer-based random number generator. Enrolled patients are prospectively monitored for neurological recovery, functional disability using the pediatric Liverpool Outcome Score (LOS), radiological resolution on neuroimaging (MRI), overall survival, and treatment-emergent adverse events.

Read the detailed description

Acute Disseminated Encephalomyelitis (ADEM) is an immune-mediated demyelinating inflammatory disorder of the central nervous system predominantly affecting pediatric patients. While high-dose intravenous corticosteroids (such as methylprednisolone) serve as the standard first-line treatment, a clinical subset of patients fails to respond, presenting persistent neurological deficits, neurodevelopmental sequelae, or fulminant clinical deterioration.

This prospective, randomized, open-label comparative clinical trial is designed to evaluate the therapeutic efficacy, neuroimaging resolution, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy in pediatric patients under 14 years of age with steroid-refractory ADEM.

Eligible participants (a total of 30 pediatric patients) are randomized in a 1:1 ratio using a computer-generated random number sequence into two equal treatment arms: 15 patients in the experimental arm receive intravenous cyclophosphamide pulse therapy (500 mg/m2) combined with intensive hydration and Mesna uroprotection to prevent hemorrhagic cystitis, while 15 patients in the active comparator arm receive standard intravenous immunoglobulin (IVIG) immunomodulatory therapy (2 g/kg).

Longitudinal monitoring is performed across both cohorts to assess neurological functional recovery and disability using the pediatric-validated Liverpool Outcome Score (LOS), radiological clearance on brain and spine MRI, overall survival up to 24 months, and the active surveillance of treatment-emergent adverse events.

02

Conditions studied

  • Acute Disseminated Encephalomyelitis

Keywords

  • Acute Disseminated Encephalomyelitis
  • ADEM
  • Central Nervous System Demyelinating Autoimmune Diseases
03

In context

Demyelinating Autoimmune Diseases, CNS

26 studies on the registry are indexed under Demyelinating Autoimmune Diseases, CNS; 9 are open to participants now.

This study's planned enrollment of 30 is below the median of 46 across 20 interventional studies indexed under Demyelinating Autoimmune Diseases, CNS.

Browse Demyelinating Autoimmune Diseases, CNS studies →

Lead sponsor

Damascus University is the lead sponsor of 214 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 13 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients younger than 14 years of age (\< 14 years) at clinical presentation.
  • Confirmed diagnosis of Acute Disseminated Encephalomyelitis (ADEM) fulfilling the consensus criteria defined by the International Pediatric Multiple Sclerosis Study Group (IPMSSG).
  • - clinical status, defined as active disease persistence, neurological deterioration, or absence of significant functional improvement following a 3-5 day course of high-dose intravenous methylprednisolone pulse therapy (20-30 mg/kg/day).
  • Intact baseline renal function (serum creatinine and BUN within age-adjusted normal physiological ranges).
  • Intact baseline hepatic function (, ALT, and within acceptable limits).
  • Absence of active systemic sepsis, bacteremia, or acute uncontrolled systemic infection at baseline.
  • Formal written obtained from parents or legal guardians.

Exclusion criteria

Exclusion Criteria:

  • Patients aged 14 years and older (≥ 14.0 years).
  • Pre-existing significant renal insufficiency, acute kidney injury, or chronic renal disease.
  • Pre-existing hepatic failure, cirrhosis, or acute severe hepatic injury.
  • Active systemic sepsis or uncontrolled severe systemic infection.
  • Pre-existing severe bone marrow suppression (baseline ANC ≤ 1500/mm³ or count \< 50,000/mm³).
  • History of known to cyclophosphamide, Mesna, or immunoglobulin preparations.
  • Alternative neuroinflammatory or metabolic diagnosis confirmed.
  • Refusal of parents or legal guardians to grant written .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cyclophosphamide IV

    Fifteen pediatric patients (\<14 years) with steroid-refractory ADEM randomized to this experimental group will receive intravenous cyclophosphamide pulse therapy as rescue treatment.

    Drug: Cyclophosphamide

  • Active comparator
    Intravenous Immunoglobulin (IVIG)

    Fifteen pediatric patients (\<14 years) with steroid-refractory ADEM randomized to this active comparator group receive intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy for ADEM.

    Drug: Intravenous immunoglobulin (IVIG)

Interventions

  • Administered as intravenous pulse therapy at a dosage of 500 mg/m² body surface area. Delivered with intensive pre- and post-hydration protocols along with Mesna (2-mercaptoethane sulfonate sodium) uroprotection to mitigate acrolein-induced hemorrhagic cystitis.

  • DrugImmunoglobulins, IntravenousStudies of Immunoglobulins, IntravenousImmunoglobulins, Intravenous pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered at a total immunomodulatory dose of 2 g/kg body weight, infused according to standard pediatric institutional protocols (either 1 g/kg/day for 2 consecutive days or 400 mg/kg/day over 5 consecutive days), under continuous hemodynamic monitoring.

06

What researchers measure

Primary outcomes

  1. Neurological Functional Outcome and Disability Assessment by Liverpool Outcome Score (LOS)

    Evaluation of functional recovery and post-encephalitic neurological sequelae using the pediatric-validated Liverpool Outcome Score (LOS). The LOS stratifies pediatric neuro-outcomes into 5 distinct categories: * Score 5: Full recovery (resumed normal activities / baseline abilities) * Score 4: Minor sequelae (mild behavioral changes or mild motor deficits with full independence) * Score 3: Moderate sequelae (independent in basic daily self-care but impaired in higher tasks) * Score 2: Major sequelae (severe physical or cognitive impairment, dependent on caregivers) * Score 1: Death

    Time frame: Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.

Secondary outcomes

  1. Radiological Resolution on Neuroimaging (Brain & Spine MRI)

    Quantitative and qualitative reduction or total resolution of hyperintense demyelinating lesions on T2/FLAIR sequences, resolution of contrast enhancement, and absence of new active or demyelinating lesions.

    Time frame: Assessed at 2,4 and 12 weeks post-treatment initiation.

  2. Overall Survival and All-Cause Mortality Rate

    Proportion of pediatric patients surviving without fatal disease complications or fulminant progression throughout the study observation window.

    Time frame: Up to 24 months

  3. Treatment-Emergent Adverse Events & Tolerability

    Incidence and severity of adverse drug reactions including bone marrow suppression (CBC) and hemorrhagic cystitis (Urinalysis)

    Time frame: Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.

07

Study locations

1 of 1 sites recruiting
  • Children's University Hospital
    Damascus, Syria
    Recruiting
08

References and documents

Publications

  • Ayed H, Chaudhary MW, AlBaradie R, Mir A. Use of Cyclophosphamide in a Child With Fulminant Acute Disseminated Encephalomyelitis. Child Neurol Open. 2018 Mar 11;5:2329048X18754631. doi: 10.1177/2329048X18754631. eCollection 2018. PubMed 29560383 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Feb 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartActual
Mar 17, 2025
Primary completionEst.
Feb 17, 2027
CompletionEst.
Mar 17, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949838
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Mar 17, 2025
Primary completion
Feb 17, 2027 (estimated)
Completion
Mar 17, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Fatima Amer, MD
Contact
Fatema.amer@damascusuniversity.edu.sy
+963 966494768
Fatima Amer, MD
principal investigator · Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
Sameer Baqla, PhD
study director · Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
Sally Kadoura, PhD
study director · Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syrian Arab Republic

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclophosphamide

Start the discussion